Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
September 22, 2023

FDA approves Krystal Biotech’s KB408 for AATD treatment

The US Food and Drug Administration (FDA) has granted clearance to Krystal Biotech’s investigational new drug application (IND) for KB408 to treat alpha-1 antitrypsin deficiency (AATD), a rare genetic disease.

KB408 is intended for the treatment of alpha-1 antitrypsin deficiency. Credit: Jerad M Gardner/